The Business of Biofabrication

Funding supports ISO 13485-compliant production and expansion into regulated markets

Strategic Financing Round Advances Commercial Growth

Nova Scotia-based biomaterials company 3DBioFibR has raised CAD $3 million in an equity financing round to scale its dry-spinning platform for manufacturing high-performance biopolymer fibers. The round was led by AoA (Angel of Angels) Ventures, with participation from Build Ventures, Invest Nova Scotia, and Concrete Ventures. This funding will enable the company to expand its manufacturing capacity and establish an ISO 13485-compliant clean room facility.

The investment supports 3DBioFibR’s transition from product development to scalable commercial production across multiple sectors, including regenerative medicine, surgical devices, cosmetics, apparel, and defense.

Proprietary Manufacturing Platform for Clinical-Grade Biomaterials

3DBioFibR’s core innovation lies in its dry-spinning technology, which produces collagen and spider silk fibers with mechanical strength up to 2x that of native tissue. The process offers over 3,600 times the production throughput of conventional wet-spinning or electrospinning methods, with significantly improved uniformity.

This level of scale and precision positions 3DBioFibR to become a preferred supplier for clinical and industrial applications requiring consistent, high-strength biomaterials.

Market Traction and Commercial Partnerships

The company reports active development agreements with undisclosed partners across medical device and biotechnology industries. These collaborations validate the technical and commercial viability of its fibers in regulated environments and support further adoption in surgical, tissue engineering, and drug discovery applications.

CEO Kevin Sullivan emphasized the strategic nature of the investment, stating that it “fuels the next phase of our growth and enables delivery of clinical-grade fibers to partners building the next generation of biomaterial-based solutions.”

Industry Response and Investor Commentary

Investors have highlighted the platform’s scalability and cross-industry relevance:

• Build Ventures called 3DBioFibR “a benchmark setter” in the field of biopolymer manufacturing.
  
• Invest Nova Scotia emphasized the company’s ability to “redefine” what’s possible in multibillion-dollar verticals ranging from health to defense.
  

Regulatory Readiness and Outlook

The new funding will support construction of a clean room facility and implementation of ISO 13485 standards, a key requirement for manufacturers operating in medical and regulated spaces. This infrastructure investment is expected to position the company for GMP-compliant production and entry into clinical-grade material supply chains.

---

About 3DBioFibR

3DBioFibR is a Canadian biomaterials company developing scalable, high-performance collagen and spider silk fibers for use in regenerative medicine, surgical applications, cosmetics, defense, and advanced textiles. Its patented dry-spinning process enables production of uniform, mechanically robust fibers that can meet regulatory and commercial demands across industries.

For more info visit https://3dbiofibr.com/